{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:08:34Z","timestamp":1787004514774,"version":"build-2736575974"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":1464,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1998,1]]},"abstract":"<jats:p>\n                    <jats:bold>\n                      <jats:italic>Aims<\/jats:italic>\n                    <\/jats:bold>\n                    \u2007To determine the induction effect of rifampicin on the activity of 4\u2032\u2010hydroxylase in poor metabolizers (PMs) with m\n                    <jats:sub>1<\/jats:sub>\n                    mutation of S\u2010mephenytoin 4\u2032\u2010hydroxylation and the relationship of the effect with gene dose.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Methods<\/jats:italic>\n                    <\/jats:bold>\n                    \u2007Seven extensive metabolizers (EMs) of S\u2010mephenytoin 4\u2032\u2010hydroxylation and five PMs with m\n                    <jats:sub>1<\/jats:sub>\n                    mutation were chosen to take rifampicin 300\u2003mg day\n                    <jats:sup>\u22121<\/jats:sup>\n                    orally for 22 days. Prior to and after rifampicin treatment, each subject was given racemic mephenytoin 100\u2003mg. The 4\u2032\u2010hydroxymephenytoin (4\u2032\u2010OH\u2010MP) excreted in the 0\u201324\u2003h urine and mephenytoin S\/R ratio in the 0\u20138\u2003h urine were determined by h.p.l.c. and GC, respectively.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Results<\/jats:italic>\n                    <\/jats:bold>\n                    \u2007In all EMs, the excretion of 4\u2032\u2010OH\u2010MP in the 0\u201324\u2003h urine was increased by 146.4\u00b117.9%, 0\u20138\u2003h urinary mephenytoin S\/R ratio was decreased by 77.3\u00b18.8%, the percentage increase in the 0\u201324\u2003h excretion of 4\u2032\u2010OH\u2010MP in those CYP2C19 homozygous (wt\/wt) was greater than that in those heterozygous (wt\/m\n                    <jats:sub>1<\/jats:sub>\n                    and wt\/m\n                    <jats:sub>2<\/jats:sub>\n                    \u200a) (203.9\u00b142.5%\n                    <jats:italic>vs<\/jats:italic>\n                    69.6\u00b14.1%). 0\u20138\u2003h urinary mephenytoin S\/R ratio of those PMs with m\n                    <jats:sub>1<\/jats:sub>\n                    mutation was decreased by 9.6%, the amount of 4\u2032\u2010OH\u2010MP excreted in the 0\u201324\u2003h urine was increased by 80.1\u00b148.0%.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Conclusions<\/jats:italic>\n                    <\/jats:bold>\n                    \u2007The activity of 4\u2032\u2010hydroxylase of PMs with m\n                    <jats:sub>1<\/jats:sub>\n                    mutation of S\u2010mephenytoin 4\u2032\u2010hydroxylation can be induced by rifampicin and the inducing effect of rifampicin on 4\u2032\u2010hydroxylase is gene dependent.\n                  <\/jats:p>","DOI":"10.1046\/j.1365-2125.1998.00643.x","type":"journal-article","created":{"date-parts":[[2003,3,10]],"date-time":"2003-03-10T23:29:46Z","timestamp":1047338986000},"page":"27-29","source":"Crossref","is-referenced-by-count":43,"title":["The induction effect of rifampicin on activity of mephenytoin 4\u2032\u2010hydroxylase related to M1 mutation of CYP2C19 and gene dose"],"prefix":"10.1111","volume":"45","author":[{"given":"Hua\u2010Jun","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song\u2010Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong\u2010Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.5"},{"key":"e_1_2_5_3_2","first-page":"768","article-title":"Family studies of mephenytoin hydroxylation deficiency.","volume":"38","author":"Inaba T","year":"1986","journal-title":"Am J Hum Gen"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.114"},{"key":"e_1_2_5_5_2","first-page":"5422","article-title":"The major genetic defect responsible for the polymorphism of S\u2010Mephenytoin metabolism in humans.","volume":"269","author":"De Morais SMF","year":"1994","journal-title":"J Biol Chem"},{"key":"e_1_2_5_6_2","first-page":"594","article-title":"Identification of a new genetic defect responsible for the polymorphism of S\u2010mephenytoin metabolism in Japanese.","volume":"46","author":"De Morais SMF","year":"1994","journal-title":"Mol Pharmacol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00173a017"},{"key":"e_1_2_5_8_2","first-page":"662","article-title":"Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.","volume":"234","author":"Wedlund PJ","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb03799.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90053-5"},{"key":"e_1_2_5_11_2","first-page":"389","article-title":"The effect of gene dose on the activity of S\u2010mephenytoin hydroxylase.","volume":"76","author":"Xiao ZS","year":"1996","journal-title":"J Clin Med"},{"key":"e_1_2_5_12_2","first-page":"277","article-title":"Application of gas chromatography to determine the concentration of S\u2010mephenytoin and R\u2010mephenytoin in human urine.","volume":"15","author":"Huang SL","year":"1997","journal-title":"Chromatography"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","unstructured":"XieHG HuangSL ZhouHHHigh\u2010performance liquid chromatographic determination of urinary 4\u2032\u2010hydroxymephenytoin a metabolic marker for the hepatic enzyme CYP2C19 in humans.J Chromatography1995;B:1\u20137","DOI":"10.1016\/0378-4347(95)00065-Q"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archinte.1992.00400160029007","article-title":"Update on rifampicin drug interaction II.","volume":"152","author":"Shawn MB","year":"1992","journal-title":"Arch Intern Med"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02432.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/dna.1991.10.545"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199412000-00001"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1998.00643.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1998.00643.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2125.1998.00643.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1998.00643.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T21:47:00Z","timestamp":1694382420000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1998.00643.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,1]]}},"alternative-id":["10.1046\/j.1365-2125.1998.00643.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00643.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,1]]}}}